Melanoma: Complete response to anti-PD-1s 'generally durable'

But the results of retreating relapsed patients are disappointing, say researchers

Three years after starting anti-PD-1 therapy, most patients who have complete response maintain that status despite stopping their treatment.

Intravenous infusion

A real-world study of US patients with advanced melanoma shows that complete response can be maintained for 21 months without further anti-PD-1 therapy but reveals “disappointing” results for patients who relapse and are retreated.

The analysis of data from 396 patients with unresectable stage III or stage IV melanoma, at the Memorial Sloane